Pharmacological composition of ready combined tablets

FIELD: pharmacology.

SUBSTANCE: invention relates to field of pharmacology and concerns compositions of ready combined tablets. Composition of ready combined tablets includes g: aspirin 0.24; phenacetin 0.18; caffeine 0.03; sugar in powder 0.1; citrus skin 0.45.

EFFECT: by pharmacological action composition of ready combined tablets is close to "Citramon", but in contrast to it is enriched with vitamins of B group, vitamin C, organic acids, essential oils, pectic substances.

 

The invention relates to the field of pharmacology, and relates to compositions prepared the combined pill.

Known composition prepared combined pill "Aspirin", which includes, g: aspirin 0,24; phenacetin 0,18; caffeine 0,03; cocoa powder 0,03; citric acid of 0.02; the sugar in the powder of 0.5 [1].

The objective of the invention is to reduce the irritating effect of acetylsalicylic acid on mucous, enrichment ready combined pills with vitamins, fiber, organic acids, essential oils, pectin substances.

The technical solution of the task is achieved by the fact that the pharmacological composition prepared the combined pill, including aspirin, phenacetin, caffeine, sugar powder additionally contains dried and milled to a powder, citrus peel in the following ratio of components, g: aspirin 0,24; phenacetin 0,18; caffeine 0,03; sugar powder 0,1; peel of citrus 0,45.

For preparation of the composition can be used the peel of any citrus fruit (oranges, tangerines, grapefruits, lemons, etc. in any combination.

Peel citrus, pre-washed from dirt, dried at a temperature of 45-65°C to a moisture content of 1-5%, and pulverized to obtain a powder with a specific surface area 2500-4500 cm2/year Components are metered in number is: aspirin 0,24; phenacetin 0,18; caffeine 0,03; sugar powder 0,1; peel of citrus 0,45. The components are mixed. From the obtained composition is produced tablets of 0.25 and 0.5 g

Pharmacological composition prepared the combined pill, which can be used for headache, neuralgia, catarrhal diseases, allows to reduce the irritant effect of acetylsalicylic acid on mucous membranes enriched with b vitamins, vitamin C, fiber, organic acids, essential oils, pectin substances.

Sources of information

1. Mashkovsky PPM Medicines (manual for doctors). - Chisinau: State publishing Changes of Moldoveneasca", 1962. - P.70-71.

Pharmacological composition prepared the combined pill, including aspirin, phenacetin, caffeine, sugar powder, characterized in that it further comprises dried and milled to a powder, citrus peel in the following ratio of components, g: aspirin 0,24; phenacetin 0,18; caffeine 0,03; sugar powder 0,1; peel of citrus 0,45.



 

Same patents:

FIELD: pharmacology.

SUBSTANCE: invention relates to pharmaceutical industry, in particular to production of medications used in case of upper airways diseases (rhinitis, pharyngitis, laryngitis, tracheitis); in case of neuralgia (myalgia, artralgia, migraine, cardioneurosis), stenocardia (light forms), itching dermatosis. Medication contains: menthol, eucalyptus oil, lump sugar, sodium salt of carboxymethylcellulose, talc, stearic acid or its salts, additionally containing black mint oil and aerosyl with definite component ratio. Also claimed is method of obtaining said medication.

EFFECT: increase of tablet strength, increase of tablet disintegration time.

2 cl, 2 tbl

FIELD: pharmacology.

SUBSTANCE: invention relates to medications and concerns microemulsion for transnasal diazepam introduction, including carrier, which contains water, fatty acid ester, hydrophilic surface-active substance, polar solvent and alcohol, fatty acid and water are contained in carrier in approximately equal amounts, contained amount of alcohol exceeding amount of each of surface-active substance and polar solvent. Also described is method of transnasal diazepam introduction to patient who needs it.

EFFECT: quick beginning of active substance action and improvement of absorption.

16 cl, 1 tbl

FIELD: medicine.

SUBSTANCE: inventions refer to medicine, particularly to immunotherapy, and to be used for treatment and prevention of the diseases associated with amyloid-beta (Aβ) peptide expression. Versions of the method include introduction of pharmaceutical composition in effective amount containing an antibody preferentially bonded with amino acids 28-40 peptide Aβ1-40 (SEQ ID NO: 1), also does not show considerable cross-responsiveness with peptide Aβ1-42 and Aβ1-43.

EFFECT: versions of the method to prevent allow reducing risk or delaying the diseases associated with amyloid-beta (Aβ) peptide expression, particularly Alzheimer's diseases, and versions to treat ensures reducing clinical presentations, delaying progressing of the given diseases.

46 cl, 11 tbl, 7 ex, 8 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine and concerns methods of neural disorder treatment with introducing hematopoietic growth factors. Substance of the invention includes G-CSF or its functionally active version 90% identical to human G-CSF sequence presented in SEQ ID NO:28 to be applied in therapy of amyotrophic lateral sclerosis.

EFFECT: benefit of the invention consists in neuroprotection of disease-related nerve cells.

2 cl, 38 ex, 1 tbl, 41 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to neurology and enables to treat Parkinson's disease. Method involves as follows. The baseline Parkinson's disease therapy is combined with oral introduction of antioxidant carnosine during 30 days as dosed 1.5 g daily.

EFFECT: introduction of carnosine as described above allows for reduced dopaminergic neuron injuries caused by oxidative stress ensured by higher superoxide dismutase activity.

1 ex, 1 tbl, 3 dwg

FIELD: veterinary science.

SUBSTANCE: invention refers to veterinary science, namely to curing the animals suffering from such infectious diseases as scrapie being prion disease. For this purpose birch bark extract is introduced to an animal.

EFFECT: extract introduced ensures delayed body weight reduction and prolonged life for an animal.

7 tbl, 5 dwg

FIELD: medicine.

SUBSTANCE: there is disclosed application of glycosaminoglycan fraction of apparent molecular weight 2400 (±200)D depolymerised from glycosaminoglycan chosen from heparan sulphate and heparin for preparation of pharmaceutical compositions for treating the emotional insanities chosen from depressive disorder, qualm, anxiety neurosis, agitation, mental confusion. Additionally there is disclosed emotional insanity treatment method with no excitory influence depressing effect on central nervous system.

EFFECT: it is revealed that the claimed compounds both reduced emotional reactions and improved exploratory behaviour, ensured better environmental and potential hostility adaptation.

6 cl, 4 tbl

FIELD: medicine.

SUBSTANCE: there is disclosed application of glycosaminoglycan fraction of apparent molecular weight 2400 (±200)D depolymerised from glycosaminoglycan chosen from heparan sulphate and heparin for preparation of pharmaceutical compositions for treating the emotional insanities chosen from depressive disorder, qualm, anxiety neurosis, agitation, mental confusion. Additionally there is disclosed emotional insanity treatment method with no excitory influence depressing effect on central nervous system.

EFFECT: it is revealed that the claimed compounds both reduced emotional reactions and improved exploratory behaviour, ensured better environmental and potential hostility adaptation.

6 cl, 4 tbl

FIELD: medicine.

SUBSTANCE: there is disclosed application of glycosaminoglycan fraction of apparent molecular weight 2400 (±200)D depolymerised from glycosaminoglycan chosen from heparan sulphate and heparin for preparation of pharmaceutical compositions for treating the emotional insanities chosen from depressive disorder, qualm, anxiety neurosis, agitation, mental confusion. Additionally there is disclosed emotional insanity treatment method with no excitory influence depressing effect on central nervous system.

EFFECT: it is revealed that the claimed compounds both reduced emotional reactions and improved exploratory behaviour, ensured better environmental and potential hostility adaptation.

6 cl, 4 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to neurology, and can be used in treatment of clinical presentations of multiple sclerosis. For this purpose autoblood 2-4 ml is sampled into the syringe prefilled with dexamethasone 0.25-0.5 ml and 1% lidocaine solution 8-10 ml. Autoblood is sampled from sponge tissue of scapular spine or spinous process of 4th thoracic vertebra. The mixture is injected intraosseously in autoblood sampling point or sponge tissue of the other bone.

EFFECT: therapy provides higher effectiveness with respect to clinical presentations of multiple sclerosis due to bone tissue metabolism activated and immunopoesis stimulation.

1 ex

FIELD: pharmacology.

SUBSTANCE: invention relates to pharmaceutical industry, in particular to production of medications used in case of upper airways diseases (rhinitis, pharyngitis, laryngitis, tracheitis); in case of neuralgia (myalgia, artralgia, migraine, cardioneurosis), stenocardia (light forms), itching dermatosis. Medication contains: menthol, eucalyptus oil, lump sugar, sodium salt of carboxymethylcellulose, talc, stearic acid or its salts, additionally containing black mint oil and aerosyl with definite component ratio. Also claimed is method of obtaining said medication.

EFFECT: increase of tablet strength, increase of tablet disintegration time.

2 cl, 2 tbl

FIELD: medicine.

SUBSTANCE: invention concerns chemical-pharmaceutical industry and concerns anti-inflammatory, analgesic and antipyretic solid formulation containing ketoprofen as an active material and target additives in ratio, wt %: ketoprofen - 30-50, mixed lactose and polyvinylpyrrolidone of two types: soluble and insoluble - 40-60, colloidal silicon dioxide - 1-10, stearic acid and/or its salts - 0.5-1, potato starch - the rest.

EFFECT: invention ensures good disintegration ability and strength of a tablet, as well as its ready solubility, simplifies preparation of the formulation.

8 cl, 2 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to chemical-pharmacologic industry and concerns method of obtaining tablet sweetener, which contains aspartame and is used in dietary and diabetic nutrition to prevent sugar diabetes disease, atherosclerosis, obesity, and to fight excess weight. In obtaining sweet tablets lactose is moistened with water in amount 1.5-8.3% of lactose weight, mixed with aspartame, leucine, NaCMC, and tableted on rotor tablet press. Weight of tablets is 0.055-0.065 g. Sweetener contains 59% lactose, 33% aspartame, 4.0% sodium carbocsimethylcellulose, 4.0% L-leucine.

EFFECT: optimisation of technologic process on condition of high pressing speed (not less than 2600 tablets per minute) with constant work of tablet press during twenty-four hours without press instrument breaking down.

2 cl, 6 ex, 4 tbl

FIELD: medicine.

SUBSTANCE: claimed invention relates to field of medications, in particular to peroral mediations with retarded release, which contain at least 20 mgA of ziprazidone and substance ensuring retarded release. In addition invention relates to methods of treating patient by introduction of said dosage forms.

EFFECT: in ensuring efficient levels of ziprazidone in blood during long period of time.

44 cl, 2 dwg, 15 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medications and concerns composition of dissolving in mouth cavity film, which ensures easing nicotine addiction and contains: a) enterosoluble polimer; b) at least one alkali buffer agent and c) nicotine active agent. Also described are multi-component dissolving in mouth cavity film, which ensures easing nicotine addiction, and method of obtaining film composition, dissolving in mouth cavity.

EFFECT: invention compositions ensure good transbuccal absorption and ease nicotine addiction in people.

21 cl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns medicine drugs, particularly pharmaceutical formulation including sodium levothyroxin, microcrystalline cellulose with average particle size under 125 mcm in amount of 60 to 85 wt % of the total formulation weight, and pre-gelatinised starch in amount of 5 to 30 wt % of the total formulation weight. Additionally, invention concerns method of obtaining claimed formulation and method of hormonal thyroid disorder treatment.

EFFECT: obtaining stable solid dosed formulation of sodium levothyroxin.

16 cl, 4 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns medicine, particularly medical drugs with organic active components, medicines with sedative, vasodilating and antispasmodic effect, and methods of medicine obtainment, an can be applied in treatment of neuroses with high irritability, increased agitation, insomnia, neurocirculation dystonia, early stage of hypertension, non-acute cardiovascular spasm, digestive organ spasms related to neurovegetative disorders. Medicine of sedative and antispasmodic effect includes ethyl ether of α-bromisovaleric acid, Phenobarbital, peppermint oil, microcrystalline cellulose auxiliary substances for solid formulation obtainment in pellet form at the following component ratio, wt %: ethyl ether of α-bromisovaleric acid 1.37-8.2; Phenobarbital 1.25-7.5; peppermint oil 0.16-0.58; microcrystalline cellulose 2-15; the rest is auxiliary substances; pellets are covered with shell composed of β-cyclodextrin in amount of 10% of dry coating weight. First version of method of obtaining medicine with sedative and antispasmodic effect involves initial mixing of ethyl ether of α-bromisovaleric acid with peppermint oil, so that the mix comprises over 4.5% of total pellet, core pellet or capsule content weight, adding the mix to humid β-cyclodextrin taken in amount of up to 70% of total pellet core weight, stirring for 1-2 minutes, drying and pelletising of obtained mix, mixing granulate with Phenobarbital and microcrystalline cellulose powders and auxiliary filler, fluffer and slider substances, pellet compression and coating with shell containing β-cyclodextrin in amount of up to 10% of dry coating weight. Second version of method involves initial mixing Phenobarbital with auxiliary filler substance, separate preparation of mix of ethyl ether of α-bromisovaleric acid with peppermint oil, so that the ether oil mix comprises less than 4.5% of total pellet, core pellet or capsule content weight, adding microcrystalline cellulose powder, powders with extensive crystal surface area, auxiliary fluffer and slider substances, adding obtained mix to Phenobarbital and filler mix, pellet compression and coating with shell containing β-cyclodextrin in amount of up to 10% of dry coating weight.

EFFECT: medicine of sedative and antispasmodic effect in solid pellet form, with sedative and antispasmodic action matching that of drops with similar effect, ensuring stability of volatile components.

20 cl, 8 ex, 11 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns medicine and pharmaceutical industry, particularly pelletised formulation of clopidogrel or its pharmaceutically acceptable salt with anti-aggregation or anti-thrombotic effect, including core containing clopidogrel or its pharmaceutically acceptable salt, starch, microcrystalline cellulose, propyleneglycol, alkali metal stearate and carrier, and film shell coating the core. Additionally the core includes hydrated castor oil in amount of 2-8 wt %, and shell also includes hydroxypropylmethylcellulose in amount of 2-2.5 wt % and propyleneglycol in amount of 0.55-0.60 wt % and does not include methylcellulose. Also invention concerns method of obtainment of the pelletised formulation and its application in prevention of thrombotic and atherothrombotic states accompanied by increased thrombocyte aggregation.

EFFECT: high physical and chemical storage stability, fast decomposition upon oral administration, simplified production technology at low cost.

15 cl, 3 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: present invention pertains to crystalline substance for peroral solid medicinal preparation, which is an indoline compound (KMD-3213), which exhibits blocking action to α1-adrinaline receptors, is suitable for use as a therapeutic medium in case of dysuria and is represented by formula (I) . The x-ray diffraction picture of the powder of this compound is characterised by main peaks 5.5°±0.2°, 6.1°±0.2°, 9.8°±0.2°, 11.1°±0.2°, 12.2°±0.2°, 16.4°±0.2°, 19.7°±0.2° and 20.0°±0.2°, as 2θ.

EFFECT: obtaining solid medicinal preparations for treating dysuria, containing this crystalline substance as an active ingredient.

14 cl, 3 dwg, 2 tbl, 9 ex

FIELD: medicine; pharmacology.

SUBSTANCE: pharmaceutical composition contains Topyramat as active substance and additives, including starch, lactose, microcrystalline cellulose, cross-linked polyvinylpyrrolidone and dusting agent. Preparation is produced by wet granulation technique in the form of coated tablets with 25 mg, 50 mg, 100 mg or 200 mg of Topyramat content.

EFFECT: fast decomposition, high reactant release and high durability, storage stability.

10 cl, 1 tbl, 3 ex

FIELD: pharmacology.

SUBSTANCE: invention relates to pharmaceutical industry, in particular to production of medications used in case of upper airways diseases (rhinitis, pharyngitis, laryngitis, tracheitis); in case of neuralgia (myalgia, artralgia, migraine, cardioneurosis), stenocardia (light forms), itching dermatosis. Medication contains: menthol, eucalyptus oil, lump sugar, sodium salt of carboxymethylcellulose, talc, stearic acid or its salts, additionally containing black mint oil and aerosyl with definite component ratio. Also claimed is method of obtaining said medication.

EFFECT: increase of tablet strength, increase of tablet disintegration time.

2 cl, 2 tbl

Up!